THE DISCOVERY OF NEW PHARMACOLOGICAL TREATMENTS FACES A MAJOR OBSTACLE
– Partial view of information, lack of reliability and predictive power –
A vast but fragmented body of scientific literature
Needs to be deciphered into simpler messages
OUR PREDICTIVE PLATFORM DEVELOPED FOR TARGET IDENTIFICATION
Existing solutions are comparable to "high-throughput" screening of compound libraries using mathematical tools with low predictive power and anticipation of efficiency.
RECOMMENDATIONS GENERATED
Relevant biological targets or pathways, molecules with real therapeutic potential, methods for using the molecules to create intellectual property.
ADDED VALUE
Strong predictive power, analysis speed and depth, highly effective alternative to large-scale screening, synergies identification to optimize the drug candidate patentability.
A SEARCH FOR SYNERGIES TO OPTIMIZE THERAPEUTIC VALUE AND SECURE INTELLECTUAL PROPERTY
+ Ability to prepare the in vitro POC and protecting innovation (patent application)
INNOVATIVE DRUG CANDIDATES ALREADY IDENTIFIED BY OUR PLATFORM
Our bioinformatics platform overcomes the potential limits of traditional drug repurposing and generates new synergistic and patentable candidates.
OTHER ALGORITHMS UNDER DEVELOPMENT TO OPTIMIZE PRE-CLINICAL TRIALS
Second observation | Preclinical data are rich but insufficiently exploited and animal experimentation is essential but requires rational and informed planning.
Prediction of experimental design
OBJECTIVE | Optimize preclinical experimental stages by leveraging internal CRO data on incurable and debilitating diseases
HOW IT WORKS | Analysis of internal databases and automated recommendations using a dedicated algorithm
GENERATED RECOMMENDATION
Optimal experimental protocol
Preclinical in silico modeling
OBJECTIVE | Simulating the effect of therapeutic candidates in silico to improve preclinical predictability of available models
HOW IT WORKS | Dynamic physiological models and anticipation of therapeutic effects before in vivo trials
GENERATED RECOMMENDATION
Doses, routes of administration, and models
THE PARTNERS BEHIND CXS THERAPEUTICS
Collaborators with complementary expertise, working together to develop an integrated approach to discovering new treatments.
GUILLAUME BRACHET
Partner and President
Hospital pharmacist, researcher and expert in biopharmaceuticals, vaccinology and pharmacology, consultant in pharmaceutical innovation.
NADINE MACKENZIE
Partner and Medical Director
Rheumatologist, medical director in the pharmaceutical industry for 20 years, and former member of the Management Committee of LEO Pharma France.
Anthony Alioui
Partner and CSO
PhD in genetics and molecular physiology, founder of MS PEDAGO (health promotion organization) and expert in educational engineering and communication.
PHILIPPE NUSSBAUMER
Partner
Expert in the creation and development of innovative companies, co-founder of the biotech company ALAXIA, co-founder of an early stage Deeptech investment fund.
DJMACHID DALILI
Partner
Polytechnic and PhD in nuclear physics, founder of the 3W Academy (developer school), founder and CEO of medtech DIAMPARK (Parkinson disease dedicated tool).
GABRIELLE GACHE
Partner
Master's degree in economics and MBA (HEC). Market access and pharmaceutical B-Dev. for 30 years. Member of the Board of Directors of the Swiss licensing group from 2015 to 2022.
Gregory Arbia
Partner and CFO
Doctor of Applied Mathematics. Expert in business development and financing for research companies. Co-founder of CHOICE Consulting.
DANIEL BARON
Genomic data scientist
Doctor of Science in Genetics and Genomics. Head of the platform for predicting and screening innovative drug candidates at CXS Therapeutics.
MADELEINE MURRAY
Data analyst / Developer
Doctorate in bioinformatics. Database analysis specialist and software developer. Head of Programming and AI at CXS Therapeutics.
Find out more about the Parkinson's hit on SAPPIENS
SAPPIENS is a subsidiary created following the identification of this first drug candidate by CXS Therapeutics. Its objective is to carry out the pharmaceutical development of a first neuroprotective treatment, the CXS003.
OUR PARTNERS
THEY SUPPORT US
